ClinicalTrials.Veeva

Menu

Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry in Children and Adolescents (EBECA)

U

University Children's Hospital Basel

Status

Enrolling

Conditions

Type 1 Diabetes
Neurological Disorders
Respiratory Diseases

Treatments

Diagnostic Test: Real-time SESI-MS breath analysis
Diagnostic Test: Saliva analysis
Diagnostic Test: Off-line breath analysis
Diagnostic Test: Urine analysis
Diagnostic Test: Blood analysis

Study type

Observational

Funder types

Other

Identifiers

NCT04461821
2020-00778 ks20Sinues;

Details and patient eligibility

About

This study is to investigate breath analysis (breath metabolomics) combined with established bioinformatic tools as a platform for companion diagnostics.

Full description

Therapeutic drug monitoring (TDM) is defined as measuring concentrations of a drug at one or more time points in a biological matrix after a dose. The purpose of TDM is to individualize the drug dose to achieve maximum efficacy and at the same time minimize toxicity. The concept of TDM could potentially be even more valuable if in addition to drug concentrations, other drug-regulated and drug-related metabolites could be included in the models to define optimal dosage. There exists a clinical need to stratify patients with better precision to improve current clinical and therapeutic management. Breath analysis offers an opportunity to non-invasively retrieve relevant information on the ongoing internal biochemical processes, as well as to monitor the respiratory system itself. For breath analysis, a Secondary Electrospray ionization - mass spectrometry (SESI-MS) breath analysis platform will be used to capture disease-related, drug-regulated and drug-related metabolites (breath metabolomics) in exhaled breath. This information, retrieved in parallel to standard of care clinical co-variates, could have the potential to provide a more personalized therapeutic management of patients.

Enrollment

3,600 estimated patients

Sex

All

Ages

Under 22 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 0 ≤ 22 years at study entry and signed informed consent

Additional inclusion criteria for respiratory disease population:

  • Acute disease: - Acute signs for a respiratory disease, indicated by e.g. increased work of breathing (e.g. dyspnea, increased respiratory rate), cough or wheezing.
  • Chronic disease: - Suspected or confirmed chronic airway disease (e.g. asthma).

Additional inclusion criteria for neurological disease population:

  • Acute disease: - Acute presentation or report within 24 hours of any signs of neurological deficit (motor function, sensoneural, or verbal).
  • Chronic disease: - Confirmed chronic neurologic disease (e.g. childhood epilepsy).

Additional inclusion criteria for T1D disease population:

  • Acute disease: - Hyperglycemia and/or pH (venous) <7.3, bicarbonate >10 mmol/L, increased levels of acetone in blood or urine in the context of newly diagnosed or known T1D.
  • Chronic disease: - Confirmed diagnosis of T1D

Exclusion criteria

  • Physical or intellectual impairment precluding protocol adherence.

Additional exclusion criteria for respiratory disease population:

  • Known malignancy, active smoker (passive smoke exposure is not an exclusion criterium), known inflammatory diseases (e.g. autoimmune disease) that require medical and/or pharmacological treatment and is associated with an inflammatory response, relevant congenital defects

Additional exclusion criteria for neurological disease population:

  • Known malignancy, active smoker (passive smoke exposure is not an exclusion criterium), known inflammatory diseases (e.g. autoimmune disease) that require medical and/or pharmacological treatment and is associated with an inflammatory response, relevant congenital defects.

Additional exclusion criteria for T1D population:

  • Known malignancy, active smoker (passive smoke exposure is not an exclusion criterium), relevant congenital defects.

Trial design

3,600 participants in 12 patient groups

obstructive bronchitis/bronchiolitis
Treatment:
Diagnostic Test: Blood analysis
Diagnostic Test: Off-line breath analysis
Diagnostic Test: Real-time SESI-MS breath analysis
pneumonia
Treatment:
Diagnostic Test: Blood analysis
Diagnostic Test: Off-line breath analysis
Diagnostic Test: Real-time SESI-MS breath analysis
asthma
Treatment:
Diagnostic Test: Blood analysis
Diagnostic Test: Off-line breath analysis
Diagnostic Test: Real-time SESI-MS breath analysis
neurological diseases
Treatment:
Diagnostic Test: Blood analysis
Diagnostic Test: Off-line breath analysis
Diagnostic Test: Real-time SESI-MS breath analysis
type 1 diabetes (T1D)
Treatment:
Diagnostic Test: Urine analysis
Diagnostic Test: Blood analysis
Diagnostic Test: Off-line breath analysis
Diagnostic Test: Saliva analysis
Diagnostic Test: Real-time SESI-MS breath analysis
pharmacotherapy with bronchodilators
Treatment:
Diagnostic Test: Blood analysis
Diagnostic Test: Off-line breath analysis
Diagnostic Test: Real-time SESI-MS breath analysis
pharmacotherapy with antibiotics
Treatment:
Diagnostic Test: Blood analysis
Diagnostic Test: Off-line breath analysis
Diagnostic Test: Real-time SESI-MS breath analysis
pharmacotherapy with antiviral medication
Treatment:
Diagnostic Test: Blood analysis
Diagnostic Test: Off-line breath analysis
Diagnostic Test: Real-time SESI-MS breath analysis
pharmacotherapy with antifungal medication
Treatment:
Diagnostic Test: Blood analysis
Diagnostic Test: Off-line breath analysis
Diagnostic Test: Real-time SESI-MS breath analysis
pharmacotherapy with antiepileptic medication
Treatment:
Diagnostic Test: Blood analysis
Diagnostic Test: Off-line breath analysis
Diagnostic Test: Real-time SESI-MS breath analysis
pharmacotherapy with immuno suppressants and immune-modulati
Treatment:
Diagnostic Test: Blood analysis
Diagnostic Test: Off-line breath analysis
Diagnostic Test: Real-time SESI-MS breath analysis
pharmacotherapy with anesthesia (including sedating, analges
Treatment:
Diagnostic Test: Blood analysis
Diagnostic Test: Off-line breath analysis
Diagnostic Test: Real-time SESI-MS breath analysis

Trial contacts and locations

1

Loading...

Central trial contact

Mélina Richard; Pablo Sinues, Prof. Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems